Skip to content
OmniAb
  • About
    • Overview
    • Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Antigen Design
    • Antibody Generation
      • OmniRat
      • OmniMouse
      • OmniChicken
      • OmniTaur
      • Bispecific Platforms
    • Screening
      • GEM
      • xPloration
    • Antibody Optimization
    • Ion Channel and Transporter Technology
    • Scientific Publications
  • Partnerships
    • Overview
    • Why Partner with OmniAb?
    • Partner Pipeline
    • Contact Business Development
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Stock Info
    • SEC Filings
    • Governance
      • Governance Documents
      • Executive Officers
      • Board of Directors
      • Board Committees
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts
  • Contact
OmniAb
  • About
    • Overview
    • Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Antigen Design
    • Antibody Generation
      • OmniRat
      • OmniMouse
      • OmniChicken
      • OmniTaur
      • Bispecific Platforms
    • Screening
      • GEM
      • xPloration
    • Antibody Optimization
    • Ion Channel and Transporter Technology
    • Scientific Publications
  • Partnerships
    • Overview
    • Why Partner with OmniAb?
    • Partner Pipeline
    • Contact Business Development
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Stock Info
    • SEC Filings
    • Governance
      • Governance Documents
      • Executive Officers
      • Board of Directors
      • Board Committees
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts
  • Contact

High throughput single B-cell screening for monoclonal antibodies

  • Screening
  • GEM
  • xPloration

Screening the broadest antibody repertoires with cutting-edge screening technologies to deliver the best drug candidates

Large repertoires of human sequence antibodies can present a challenge in identifying the antibodies with the most optimal candidate drug profiles from millions of possibilities. OmniAb’s robust high throughput single B-cell screening technologies enable deep searches into immune repertoires to identify unique antibodies with superior target profile. Discover GEM and xPloration®, OmniAb’s proprietary screening technologies that allow high throughput phenotypic profiling of antibodies produced by single primary B cells and rapid cloning of their variable regions. These parallel workflows provide efficient processes to retrieve large panels of hits even against difficult targets such as GPCRs or ion channels.

Screen for monoclonal antibodies with GEM, a robust single B-cell screening technology that enables deep searches into immune repertoires to identify unique antibodies.

Learn About GEM

xPloration provides rapid AI-powered HT screening and recovery processes of single B cells through deep searches into immune repertoires to identify unique antibodies with special properties in hours.

Learn About xPloration

About

  • Overview
  • Team
  • Board of Directors
  • Careers

Partnerships

  • Overview
  • Why Partner with OmniAb?
  • Partner Pipeline
  • Contact Business Development

Technology

  • Overview
  • Antigen Design
  • Antibody Generation
  • Screening
  • Antibody Optimization
  • Ion Channel and Transporter Technology
  • Scientific Publications

OmniAb, Inc.
5980 Horton Street
Suite 600
Emeryville, CA 94608

[email protected]
[email protected]

Contact | Privacy Policy | Disclaimer

© 2023 OmniAb, Inc. All rights reserved.